N
The startup develops a therapeutic drug platform targeting fibrosis through clinical trials, focusing on conditions such as wet macular degeneration, non-alcoholic steatohepatitis, and pulmonary fibrosis. This platform addresses the unmet medical need for effective treatments in patients suffering from refractory fibrosis diseases.
성남시, 대한민국
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a therapeutic drug platform targeting fibrosis through clinical trials, focusing on conditions such as wet macular degeneration, non-alcoholic steatohepatitis, and pulmonary fibrosis. This platform addresses the unmet medical need for effective treatments in patients suffering from refractory fibrosis diseases.